Internal Medicine 1007 - Internal Medicine Alert - Apr 15, 2006

Target Audience:

This activity is intended for the internist and family practitioner.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been reviewed and is acceptable for up to 1 Prescribed credit by the American Academy of Family Physicians. AAFP accreditation begins 01/01/06. Term of approval is for one year from this date. Credit may be claimed for 1 year from the date of this issue.

Credit Designation:

AHC Media designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Editor
Stephen Brunton, MD
Clinical Professor
University of California
Irvine

Peer Reviewer
Gerald Roberts, MD
Assistant Clinical Professor of Medicine
Albert Einstein College of Medicine
New York, NY

Associate Editors
Ralph R. Hall, MD, FACP, FACSM
Emeritus Professor of Medicine
University of Missouri-Kansas City School of Medicine

Allan J. Wilke, MD
Residency Program Director
Associate Professor of Family Medicine
University of Alabama at Birmingham School of Medicine
Huntsville Regional Medical Campus
Huntsville

William T. Elliott, MD, FACP
Chair
Formulary Committee
Northern California Kaiser Permanente;
Asst. Clinical Professor of Medicine
University of California
San Francisco

James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Manager
Kaiser Permanente
Oakland, CA

Louis Kuritzky, MD
Clinical Assistant Professor
University of Florida
Gainesville

Ken Grauer, MD
Professor
Assistant Director
Family Practice Residency Program
University of Florida

Author
Dana Leifer, MD
Associate Professor
Neurology
Weill Medical College of Cornell University

Subjects:

  • What is the Risk for Coronary Heart Disease in a Type 2 Diabetic Without Other Risk Factors?
  • Warfarin: Blood-Thinner and Bone-Thinner?
  • Stroke vs Stroke Mimics: Diagnosis at the Bedside
  • Ranolazine Extended-Release Tablets (RanexaTM)
  • Clinical Briefs
  • A Not Completely Normal ECG

Objectives:

  • Describe new findings in differential diagnosis and treatment of various diseases
  • Describe controversies, advantages, and disadvantages of those advances
  • Describe cost-effective treatment regimens

Financial Disclosure:

Editor, Stephen Brunton, MD, is a consultant for Sanofi-Aventis, Ortho-McNeil, McNeil, Abbott, Novo Nordisk, Eli Lilly, Endo, EXACT Sciences, and Astra-Zeneca, and serves on the speaker’s bureau of McNeil, Sanofi-Aventis, and Ortho-McNeil. Peer reviewer Gerald Roberts, MD, Associate Editors Allan J. Wilke, MD, William T. Elliott, MD, FACP, James Chan, PharmD, PhD, and Ken Grauer, MD and Author Dana Leifer, MD all report no financial relationship to this field of study. Ralph R. Hall, MD, FACP, FACSM is a consultant for Aventis. Louis Kuritzky, MD is a consultant for GlaxoSmithKline and is on the speaker’s bureau of GlaxoSmithKline, 3M, Wyeth-Ayerst, Pfizer, Novartis, Bristol-Myers Squibb, AstraZeneca, Jones Pharma, and Boehringer Ingelheim.

Copyright 2006 AHC Media. All rights reserved.